Navigation Links
InspireMD Increases Geographic Penetration; MGuard Stent is Now Available in India
Date:5/12/2011

TEL AVIV, Israel, May 12, 2011 /PRNewswire/ -- InspireMD, Inc. (OTC BB: NSPR) ("Inspire" or the "Company"), the developer of the MGuardmesh protective stent system, is happy to announce that MGuard is now available in India. MGuard, InspireMD's flagship product is India's first mesh-based coronary stent system and received a very warm welcome by the local cardiology community.

InspireMD will distribute the MGuard stent through KTPL, one of the leading suppliers of high-tech medical equipment in India. KTPL has already closed an initial order for the MGuard stent in India.  

"Indians have one of the highest mortality and morbidity rates from Coronary artery disease (CAD) as compared to other ethnic groups and we are confident that the MGuard mesh-based coronary stent system will become a very valuable new tool in the Indian cath labs, in which AMI patients are the vast majority," stated Asher Holzer, PhD President of InspireMD.  "For the past two years, MGuard has met with much success in Europe and in South America.  India possesses highly qualified interventional cardiologists and well-equipped hospitals, and I have full confidence that the country's cardiologists will welcome this new solution to distal embolization, one of the most common side effects in PCI procedures during AMI.  We are also very glad to be teaming up with Kirloskar Technologies, a most capable partner and distributor of well known international manufacturers of high tech medical equipment in India. The initial order demonstrates the viability of this market and Kirloskar's commitment to making the MGuard a success in India."

Prof. Yaron Almagor from the Jesselson Heart Center, Shaare Zedek Medical Center, Jerusalem, was recently invited to India to present the MGuard technology.  

"We have had good experience with MGuard in preventing distal embolization in heart attack patients in my center and we were pleased to learn that recently, the European Society of Cardiology (ESC) published in their guidelines that the use of mesh-based protection may be considered for PCI of highly thrombotic or SVG lesions," commented Prof. Almagor. "I am confident that the MGuard coronary stent system will help reduce complications and improve the outcome in these types of high risk patients in India as all around the world."

"KTPL has created an exclusive division comprising of a team of committed personnel to provide the MGuard Coronary Stent System at the customer doorstep in Delhi, Mumbai, Trivandrum, Kolkata, Chandigarh, Lucknow, Hyderabad, Bengaluru, Chennai, Pune and North East. KTPL has made arrangements to deliver MGuard even in smaller towns," said Amardeep Sethi, CEO, Kirloskar Technologies.

About MGuard Coronary

MGuard presents a novel combination of a coronary stent merged with an embolic protection specifically designed for Acute MI patients. The embolic protection is comprised of an ultra-thin polymer mesh sleeve that wraps the stent. The MGuard coronary stent provides permanent embolic protection, without affecting deliverability. MGuard is CE Mark approved. Mesh-based protection is now recommended for use in the recent Guidelines of the Task force of Myocardial Revascularization of the European Society of Cardiology (ESC). The MGuardTM innovative concept has enjoyed an enthusiastic welcome from leading interventional cardiologists around the world.

About Kirloskar Technologies P. Ltd.

Kirloskar Technologies is today one of the leading suppliers of high-tech medical equipments in India. It is part of the 100-year-old, multi-billion dollar Kirloskar Group. Kirloskar Technologies has over 250 installations in 175 major government hospitals, medical colleges and private hospitals. Their business philosophy revolves around providing solutions to the customers.

About InspireMD Ltd.

InspireMD is an innovative medical device company focusing on the development and commercialization of its proprietary stent system technology, MGuard. InspireMD intends to pursue applications of this technology in coronary, carotid and peripheral artery procedures. InspireMD's common stock is listed on the OTC BB under the ticker symbol "NSPR".

Forward-looking Statements:

This press release contains "forward-looking statements." Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) market acceptance of our existing and new products, (ii) negative clinical trial results or lengthy product delays in key markets, (iii) an inability to secure regulatory approvals for the sale of our products, (iv) intense competition in the medical device industry from much larger, multi-national companies, (v) product liability claims, (vi) our limited manufacturing capabilities and reliance on subcontractors for assistance, (vii) insufficient or inadequate reimbursement by governmental and other third party payors for our products, (viii) our efforts to successfully obtain and maintain intellectual property protection covering our products, which may not be successful, (ix) legislative or regulatory reform of the healthcare system in both the U.S. and foreign jurisdictions, (x) our reliance on single suppliers for certain product components, (xi) the fact that we will need to raise additional capital to meet our business requirements in the future and that such capital raising may be costly, dilutive or difficult to obtain and (xi) the fact that we conduct business in multiple foreign jurisdictions, exposing us to foreign currency exchange rate fluctuations, logistical and communications challenges, burdens and costs of compliance with foreign laws and political and economic instability in each jurisdiction. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission, including the Company's Current Report on Form 8-K filed with the SEC on April 6, 2011. Investors and security holders are urged to read these documents free of charge on the SEC's web site at www.sec.gov. The Company assumed no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

Company Contact:
www.inspire-md.com
Jonina Ohayon
Marketing Director
jonina@inspire-md.com
OTC BB: NSPR

Investor Contact:
Jeffrey Stanlis
Partner, Hayden IR
jeff@haydenir.com
(602) 476-1821


'/>"/>
SOURCE InspireMD
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. InspireMD Announces the Enrollment of the 1st Patient in the MGuard iMOS Registry, the Registry Will Enroll 1000 Patients
2. For the First Time, at EuroPCR, InspireMD Will Provide a Sneak Preview of the Next Generation MGuard Prime(R), a State of the Art Net Protective Cobalt Chromium Stent System
3. InspireMD Becomes a Supporting Organization in the Growing Stent for Life Initiative
4. InspireMD Boosts MGuard Production Capacity
5. InspireMD to Commence Trading as a Public Company Under Ticker Symbol "NSPR"
6. InspireMD to Participate in Benchmark Company, LLC 2011 One-On-One Investor Conference
7. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
8. Cleveland Clinic Study Shows the Diabetes Drug Pioglitazone Reduces Risk of Death, Heart Attack and Stroke, but Increases Risk of Heart Failure
9. Demand for VScan Dengue Fever Test Kits Increases
10. Analysis Shows Vernakalant Hydrochloride Injection Increases Conversion to Normal Heart Rhythm in Acute Atrial Fibrillation Patients Treated Within 48 Hours of Onset
11. The Quigley Corporation Reports Third Quarter Results, Increases Investment in Pharmaceutical R&D for Diabetic Neuropathy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016 ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, ... Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast to ... The global pharmaceutical excipients market ... at a CAGR of 6.1% in the forecast period ...
(Date:6/23/2016)... -- Research and Markets has announced the addition ... to their offering. The ... commercial environment for MedImmune to enter. The US ageing population ... to drive considerable growth for effective anti-influenza medications. The introduction ... considerably, but development is still in its infancy. ...
(Date:6/23/2016)... 23, 2016 Revolutionary technology includes ... Oticon , industry leaders in advanced audiology and hearing ... Oticon Opn ™, the world,s first internet connected hearing ... IoT devices.      (Photo: http://photos.prnewswire.com/prnh/20160622/382240 ... number of ,world firsts,: , TwinLink™ - ...
Breaking Medicine Technology:
(Date:6/26/2016)... (PRWEB) , ... June 26, 2016 , ... Pixel Film ... Pro X. , "Film editors can give their videos a whole new perspective by ... Austin - CEO of Pixel Film Studios. , ProSlice Levels contains over 30 ...
(Date:6/25/2016)... Washington, D.C. (PRWEB) , ... June 25, 2016 ... ... will discuss health policy issues and applications at AcademyHealth’s Annual Research Meeting June ... share their work on several important health care topics including advance care planning, ...
(Date:6/25/2016)... Lewisville, TX (PRWEB) , ... June 25, 2016 , ... ... in the United States, named Dr. Sesan Ogunleye, as the Medical Director of its ... be the facility Medical Director of our new Mesquite location,” said Dr. James M. ...
(Date:6/25/2016)... ... ... Conventional wisdom preaches the benefits of moderation, whether it’s a matter of ... too high can result in disappointment, perhaps even self-loathing. However, those who set the ... Research from PsychTests.com reveals that behind the tendency to set low expectations ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Marcy was in a crisis. Her son ... lash out at his family verbally and physically. , “When something upset him, he couldn’t ... would use it. He would throw rocks at my other children and say he was ...
Breaking Medicine News(10 mins):